Literature DB >> 21596573

Inhibitors of histone demethylases.

Brian Lohse1, Jesper L Kristensen, Line H Kristensen, Karl Agger, Kristian Helin, Michael Gajhede, Rasmus P Clausen.   

Abstract

Methylated lysines are important epigenetic marks. The enzymes involved in demethylation have recently been discovered and found to be involved in cancer development and progression. Despite the relative recent discovery of these enzymes a number of inhibitors have already appeared. Most of the inhibitors are either previously reported inhibitors of related enzymes or compounds derived from these. Development in terms of selectivity and potency is still pertinent. Several reports on the development of functional assays have been published.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596573     DOI: 10.1016/j.bmc.2011.01.046

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  33 in total

Review 1.  KDM1 class flavin-dependent protein lysine demethylases.

Authors:  Jonathan M Burg; Jennifer E Link; Brittany S Morgan; Frederick J Heller; Amanda E Hargrove; Dewey G McCafferty
Journal:  Biopolymers       Date:  2015-07       Impact factor: 2.505

Review 2.  The role of histone demethylases in cancer therapy.

Authors:  Inga Hoffmann; Martin Roatsch; Martin L Schmitt; Luca Carlino; Martin Pippel; Wolfgang Sippl; Manfred Jung
Journal:  Mol Oncol       Date:  2012-08-07       Impact factor: 6.603

3.  Genome-wide Kdm4 histone demethylase transcriptional regulation in Drosophila.

Authors:  Amy Tsurumi; Shuang Xue; Lin Zhang; Jinghong Li; Willis X Li
Journal:  Mol Genet Genomics       Date:  2019-04-24       Impact factor: 3.291

4.  Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.

Authors:  Young K Chen; Tiziana Bonaldi; Alessandro Cuomo; Joselyn R Del Rosario; David J Hosfield; Toufike Kanouni; Shih-Chu Kao; Chon Lai; Neethan A Lobo; Jennifer Matuszkiewicz; Andrew McGeehan; Shawn M O'Connell; Lihong Shi; Jeffrey A Stafford; Ryan K Stansfield; James M Veal; Michael S Weiss; Natalie Y Yuen; Michael B Wallace
Journal:  ACS Med Chem Lett       Date:  2017-07-27       Impact factor: 4.345

5.  Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases.

Authors:  Jason R Hickok; Divya Vasudevan; William E Antholine; Douglas D Thomas
Journal:  J Biol Chem       Date:  2013-04-01       Impact factor: 5.157

Review 6.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

Review 7.  Histone lysine demethylases as targets for anticancer therapy.

Authors:  Jonas W Højfeldt; Karl Agger; Kristian Helin
Journal:  Nat Rev Drug Discov       Date:  2013-11-15       Impact factor: 84.694

Review 8.  Targeting the histone orthography of cancer: drugs for writers, erasers and readers.

Authors:  Laia Simó-Riudalbas; Manel Esteller
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

9.  Histone modifications: implications in renal cell carcinoma.

Authors:  Swathi Ramakrishnan; Leigh Ellis; Roberto Pili
Journal:  Epigenomics       Date:  2013-08       Impact factor: 4.778

10.  A developmental genetic analysis of the lysine demethylase KDM2 mutations in Drosophila melanogaster.

Authors:  Yani Zheng; Fu-Ning Hsu; Wu Xu; Xiao-Jun Xie; Xinjie Ren; Xinsheng Gao; Jian-Quan Ni; Jun-Yuan Ji
Journal:  Mech Dev       Date:  2014-07-09       Impact factor: 1.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.